BEST: Bexagliflozin CV Outcomes Trial Meets Objectives BEST: Bexagliflozin CV Outcomes Trial Meets Objectives
Topline results of a cardiovascular outcomes trial of the investigational SGLT2 inhibitor for type 2 diabetes were presented at the ADA meeting and will be part of a new drug application to the US FDA.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | New Drug Applications | SGLT2 Inhibitors